| 產(chǎn)品編號 | bs-7110R-PE |
| 英文名稱 | Rabbit Anti-DOCK1/PE Conjugated antibody |
| 中文名稱 | PE標記的細胞質(zhì)分裂付出蛋白1抗體 |
| 別 名 | 180 kDa protein downstream of CRK; Ced5; Dedicator of Cytokinesis 1; Dedicator of cytokinesis protein 1; DOCK 1; DOCK-1; DOCK 180; DOCK1; DOCK1_HUMAN; DOCK180. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領(lǐng)域 | 腫瘤 細胞生物 信號轉(zhuǎn)導 細胞凋亡 細胞自噬 G蛋白信號 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human, Mouse, Rat, Chicken, Dog, Cow, Horse, Sheep, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 215kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human DOCK1 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1. Tissue specificity: Highly expressed in placenta, lung, kidney, pancreas and ovary. Expressed at intermediate level in thymus, testes and colon. Function: Involved in cytoskeletal rearrangements required for phagocytosis of apoptotic cells and cell motility. Functions as a guanine nucleotide exchange factor (GEF), which activates Rac Rho small GTPases by exchanging bound GDP for free GTP. Its GEF activity may be enhanced by ELMO1. Subunit: Interacts with the SH3 domains of CRK and NCK2 via multiple sites. Interacts with nucleotide-free RAC1 via its DHR-2 domain. Interacts with ELMO1, ELMO2 and probably ELMO3 via its SH3 domain. Interacts with RAC1 and BAI1. Subcellular Location: Cytoplasm (Probable). Membrane (Probable). Note=Recruited to membranes via its interaction with phosphatidylinositol 3,4,5-trisphosphate (Probable). Tissue Specificity: Highly expressed in placenta, lung, kidney, pancreas and ovary. Expressed at intermediate level in thymus, testes and colon. Similarity: Belongs to the DOCK family. Contains 1 DHR-1 domain. Contains 1 DHR-2 domain. Contains 1 SH3 domain. Database links: Entrez Gene: 1793 Human Entrez Gene: 330662 Mouse Omim: 601403 Human SwissProt: Q14185 Human SwissProt: Q8BUR4 Mouse Unigene: 159195 Human Unigene: 645702 Human Unigene: 436572 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 乳腺癌轉(zhuǎn)移的新標記物DOCK1 乳腺癌是一種常常發(fā)生轉(zhuǎn)移的癌癥。將近90%的乳腺癌患者都因為癌癥擴散而死，因此，理解這一危險過程的細胞和分子基礎(chǔ)機制是十分重要的。 近日，加拿大蒙特利爾臨床研究所（Institut de recherches cliniques de Montreal, IRCM）的科學家在乳腺癌研究方面取得了一個重要的發(fā)現(xiàn)，他們確定了，一種名為DOCK1的蛋白質(zhì)可以作為潛在的靶標用于減少乳腺癌患者的癌轉(zhuǎn)移。相關(guān)研究結(jié)果刊登在了近期出版的《PNAS》上。 研究人員在乳腺癌治療方面盡管已經(jīng)取得了重要的進展，但是對于癌癥擴散的機制卻知之甚少?？茖W家正在試圖確定能夠調(diào)節(jié)癌轉(zhuǎn)移過程的蛋白質(zhì)，因為它們或許可以作為新的藥物靶標，并與現(xiàn)有的方法相結(jié)合促進治療的效果。 在這項研究中，2個主要的癌癥亞型——HER-2+型和Basal-like型，很容易轉(zhuǎn)移和復發(fā)，并最終導致患者的低生存率。該調(diào)查以HER-2+(人類表皮生長因子受體2)型為研究對象， 這代表了大約25%的乳腺癌病例。 HER2陽性腫瘤比其它類型的腫瘤更傾向于快速的發(fā)展和擴散。 研究人員解釋到，通過研究HER2+乳腺癌小鼠模型，確定了DOCK1蛋白質(zhì)是癌轉(zhuǎn)移的一個重要的調(diào)控因子。當去除了小鼠中的這一蛋白質(zhì)后，乳腺癌的肺轉(zhuǎn)移大大減少了。此外，研究發(fā)現(xiàn)DOCK1蛋白質(zhì)有助于腫瘤的生長。 為了證明DOCK1的表達與乳腺癌預(yù)后之間的關(guān)系，研究人員對包含患者基因信息的幾個數(shù)據(jù)庫進行了分析。結(jié)果發(fā)現(xiàn)，在HER-2+型或Basal-like型乳腺癌中，高水平的DOCK1與較差的預(yù)后以及疾病的復發(fā)有關(guān)。 |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
